Skip to main content
. Author manuscript; available in PMC: 2014 Aug 15.
Published in final edited form as: Cancer Res. 2013 Jun 24;73(16):5242–5252. doi: 10.1158/0008-5472.CAN-13-0690

Figure 2.

Figure 2

Intratumoral variability in gefitinib PK/PD following single oral doses of 150 mg/kg and 50 mg/kg gefitinib to mice bearing intracerebral U87/vIII tumors. A. Gefitinib brain tumor concentrations at 150 mg/kg and B. 50 mg/kg and C. PD responses based on pERK (fraction of baseline pERK) at 150 mg/kg and D. 50 mg/kg, in the regions with the lowest and highest variability. All observed points represent the mean + or − SD.